TABLE 1.
Patient characteristics
| Sex (male/female) | 38/37 |
|---|---|
| Median age (range), years | 69 (44‐88) |
| Newly diagnosed | 52 (69%) |
| Relapsed/refractory | 23 (31%) |
| Immunoglobulin subtype | |
| IgG | 46 (61%) |
| IgA | 12 (16%) |
| IgD | 3 (4%) |
| Light chain only | 13 (17%) |
| Nonsecretory | 1 (1%) |
| PS (ECOG) | |
| 0 | 26 (35%) |
| 1 | 24 (32%) |
| 2 | 10 (13%) |
| 3 | 10 (13%) |
| 4 | 5 (7%) |
| Durie and Salmon stage | |
| Ⅰ | 0 (0%) |
| Ⅱ | 23 (31%) |
| III | 52 (69%) |
| A | 61 (81%) |
| B | 14 (19%) |
| ISS stage | |
| 1 | 24 (32%) |
| 2 | 28 (37%) |
| 3 | 23 (31%) |
| Bone scale | |
| 1 | 13 (17%) |
| 2 | 45 (60%) |
| 3 | 17 (23%) |
| Previous bisphosphonate treatment | 16 (21%) |
| History of DM | 17 (23%) |
| History of SRE | 34 (45%) |
| AL amyloidosis | 4 (5%) |
| Anti‐myeloma treatment | |
| Proteasome inhibitors | 75 (100%) |
| IMiDs | 51 (68%) |
| ASCT | 25 (33%) |
ASCT, autologous stem cell transplantation; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; IMiDs, immunomodulatory drug; ISS: international staging system; PS, performance status; SRE, skeletal‐related events,